INmune Bio (NASDAQ:INMB) Downgraded to “Neutral” at B. Riley

B. Riley lowered shares of INmune Bio (NASDAQ:INMB – Get Rating) from a buy rating to a neutral rating in a report released on Tuesday morning, MarketBeat reports. B. Riley currently has $7.00 target price on the stock, down from their prior target price of $14.00.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of INmune Bio from a hold rating to a buy rating and set a $7.50 target price on the stock in a report on Friday, May 13th. Maxim Group initiated coverage on shares of INmune Bio in a report on Friday, May 6th. They set a buy rating and a $22.00 target price for the company.

Shares of INMB stock opened at $5.48 on Tuesday. The firm’s 50 day moving average price is $7.76 and its two-hundred day moving average price is $9.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 23.89 and a current ratio of 23.89. The stock has a market cap of $98.34 million, a PE ratio of -2.84 and a beta of 2.44. INmune Bio has a 52-week low of $4.63 and a 52-week high of $30.37.

INmune Bio (NASDAQ:INMB – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. During the same quarter last year, the business earned ($0.32) earnings per share. As a group, sell-side analysts predict that INmune Bio will post -2.02 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in INmune Bio during the third quarter worth about $31,000. Royal Bank of Canada raised its stake in shares of INmune Bio by 90.2% during the third quarter. Royal Bank of Canada now owns 126,411 shares of the company’s stock worth $2,455,000 after acquiring an additional 59,953 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of INmune Bio by 14.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 113,914 shares of the company’s stock worth $1,162,000 after purchasing an additional 14,591 shares during the last quarter. Fermata Advisors LLC grew its holdings in shares of INmune Bio by 39.9% in the fourth quarter. Fermata Advisors LLC now owns 17,955 shares of the company’s stock worth $183,000 after purchasing an additional 5,125 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in INmune Bio in the fourth quarter valued at $175,000. Institutional investors own 13.91% of the company’s stock.

About INmune Bio (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Featured Articles